Role of Urgent Endoscopy in Patients With Suspected Upper Gastrointestinal Bleeding

Jeemyoung Kim
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

Eun Jeong Gong
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

Myeongsook Seo
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

Jong Kyu Park
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

Sang Jin Lee
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

Koon Hee Han
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

Young Don Kim
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

Woo Jin Jeong
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

Gab Jin Cheon
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

Hyun Il Seo (redi@hanmail.net)
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea

Research Article
Abstract

The optimal timing of endoscopy in patients with acute upper gastrointestinal bleeding (UGIB) remains controversial. In this study, we investigated the clinical outcomes of urgent endoscopy in patients with symptoms suggestive of UGIB compared with elective endoscopy.

From January 2016 to December 2018, consecutive patients who visited the emergency department and underwent endoscopy for clinical manifestations of acute UGIB were eligible. Urgent endoscopy (within 6 hours) and elective endoscopy (after 6 hours) were defined as the time taken to perform endoscopy from presentation to the emergency department. The primary outcome was mortality rate within 30 days.

A total of 572 patients were included in the analysis. Urgent endoscopy was performed in 490 patient. The 30–day mortality rate did not differ between the urgent endoscopy group and the elective endoscopy group. There was no difference regarding the recurrent bleeding rate, total amount of transfusion, and length of hospital stay in both groups. In multivariate analysis, age and the amount of transfusion were factors associated with mortality.

Urgent endoscopy was not associated with lower 30–day mortality rate compared with elective endoscopy in patients with suspected of acute UGIB.

Introduction

Acute upper gastrointestinal bleeding (UGIB) is one of the most common gastrointestinal emergencies. Despite remarkable advancements in endoscopic treatments and substantial attempts in reducing mortality, the overall in-hospital mortality rate associated with UGIB is still estimated to be 10% 1. Endoscopic examination plays pivotal role in both diagnosis and treatment of UGIB 2. Current guidelines recommend perform endoscopy within 24 hours of patient presentation, while emphasizing hemodynamic stabilization before the procedure 3–6. However, optimal timing of endoscopy within 24 hours and the benefit of earlier endoscopy remains controversial.

Several studies have investigated clinical impact of urgent (within 6 hours of presentation) or early (within 12 hours) endoscopy on mortality in patients with UGIB. Some studies showed no significant difference in mortality rate between urgent and elective endoscopy groups in high-risk patients with acute UGIB 7,8. In contrast, others found that urgent endoscopy was associated with lower mortality rate in high-risk patients with acute non-variceal UGIB 9,10.

Most of previous studies included highly selected patients with non-variceal UGIB or those with high risk 7–12. However, given that the definitive diagnosis is made after endoscopic examination, these studies may not reflect real-world clinical practice. Furthermore, it is often challenging to predict the cause of bleeding and to distinguish patients at high risk who require intensive care based on symptoms and information obtained from the emergency room 13. In this study, we investigated the clinical outcomes of urgent endoscopy in patients with symptoms suggestive of UGIB compared with elective endoscopy.
Methods

From January 2016 to December 2018, 966 consecutive patients who visited the emergency department with symptoms suggestive of UGIB and underwent endoscopy were eligible. Clinical manifestations of acute UGIB included hematemesis, melena, and hematochezia. Of these, 187 patients with no evidence of UGIB on initial endoscopy and 207 patients with a follow-up period of less than 30 days were excluded. Finally, a total of 572 patients were included in the analysis.

Patient-related factors (age, sex, comorbidities, previous history of peptic ulcer, and medication history), clinical parameters (presenting symptoms, systolic blood pressure, heart rate, laboratory findings, amount of transfused red blood cell (RBC), and duration of hospital stay), and procedure-related factors (time to endoscopy, endoscopic diagnosis, and kind of hemostasis) were evaluated using medical records. The GBS was calculated, using systolic blood pressure, heart rate, hemoglobin, blood urea nitrogen, the presence of melena or syncope, and the presence of hepatic disease or cardiac disease.

Patients were divided into two groups according to the timing of endoscopy which was defined as the time taken to perform endoscopy from presentation: urgent endoscopy group (within 6 hours, n = 490, 85.7%), and elective endoscopy group (after 6 hours, n = 82, 14.3%). Endoscopic treatment was performed using techniques such as thermocoagulation, hemoclip, injection, band ligation, and combination of two or more techniques. The type of treatment was determined by endoscopist. The primary outcome was mortality rate within 30 days. Secondary outcomes included rebleeding rate within 30 days, median duration of hospital stay, and median amount of RBC transfusion.

Ethics information

Approval for accessing patient information was granted from the Institutional Review Board of Gangneung Asan Hospital (2020-03-009). As this retrospective data collection was considered anonymized by the Ethics committee, the need for patient consent was waived by the Institutional Review Board of Gangneung Asan Hospital. The study was conducted according to good clinical and scientific practices and following the ethical principles of the Declaration of Helsinki.

Results

Characteristics of study population

The baseline characteristics of the study population are summarized in Table 1. Median age of 572 patients was 63 years (range, 19–95 years) and 64.0% were male. More than 80% of the patients had comorbidities, including diabetes mellitus, cerebrovascular accident, chronic kidney disease, and liver cirrhosis. The proportion of patients who were taking antithrombotic agent at the time of admission was 23.8%, and 25 patients (4.4%) were on dual antiplatelet therapy.
| Characteristics of the study population |
|----------------------------------------|
| **Total** (N = 572) | **Urgent** (n = 490) | **Elective** (n = 82) | **P value** |
| **Age, years** | 63 (19–95) | 63 (21–95) | 62 (19–93) | 0.879 |
| **Male** | 366 (64.0) | 312 (63.7) | 54 (65.9) | 0.712 |
| **Comorbidities** | 461 (80.6) | 394 (80.4) | 67 (81.7) | 0.881 |
| **Diabetes mellitus** | 160 (28.0) | 135 (27.6) | 25 (30.5) | |
| **Cerebrovascular accident** | 63 (11.0) | 58 (11.8) | 5 (6.1) | |
| **Vascular disease** | 41 (7.2) | 34 (6.9) | 7 (8.5) | |
| **Chronic kidney disease** | 40 (7.0) | 32 (6.5) | 8 (9.8) | |
| **Liver cirrhosis** | 173 (30.2) | 153 (31.2) | 20 (24.4) | |
| **Previous peptic ulcer** | 73 (12.8) | 64 (13.1) | 9 (11.0) | 0.722 |
| **Antithrombotic agents** | 136 (23.8) | 116 (23.7) | 20 (24.4) | 0.889 |
| **Aspirin** | 100 (17.5) | 84 (17.1) | 16 (19.5) | |
| **Clopidogrel** | 42 (7.3) | 36 (7.3) | 6 (7.3) | |
| **Dual antiplatelet therapy** | 25 (4.4) | 21 (4.3) | 4 (4.9) | |
| **Warfarin** | 12 (2.1) | 11 (2.2) | 1 (1.2) | |
| **DOAC** | 16 (2.8) | 15 (3.1) | 1 (1.2) | |
| **NSAID use** | 42 (7.3) | 36 (7.3) | 6 (7.3) | 0.992 |
| **Presenting symptoms** | | | | 0.700 |
| **Hematemesis** | 297 (51.9) | 258 (52.7) | 39 (47.6) | |
| **Melena** | 233 (40.7) | 196 (40.0) | 37 (45.1) | |
| **Hematochezia** | 42 (7.3) | 36 (7.3) | 6 (7.3) | |
| **SBP, mmHg** | 115 (51–226) | 114 (51–226) | 122 (67–194) | 0.015 |
| **Heart rate, beats/min** | 97 (35–165) | 98 (35–165) | 97 (50–149) | 0.806 |

Data are shown as median (range) or number (%).  

BUN/Cr ratio, ratio of blood urea nitrogen to creatinine; DOAC, direct oral anticoagulant; NSAID, non-steroidal anti-inflammatory drug; SBP, systolic blood pressure
|                         | Total (N = 572) | Urgent (n = 490) | Elective (n = 82) | P value |
|-------------------------|-----------------|------------------|-------------------|---------|
| Hemoglobin, g/dL        | 8.9 (2.6–19.1)  | 9.1 (2.6–14.7)   | 8.8 (3.2–19.1)    | 0.339   |
| BUN/Cr ratio > 30       | 303 (53.0)      | 256 (52.2)       | 47 (57.3)         | 0.406   |
| Platelet, ×10^3/μL      | 195 (8–801)     | 196 (8–801)      | 185 (22–440)      | 0.676   |
| Prothrombin time, %     | 82 (4–137)      | 81 (4–127)       | 90 (8–137)        | 0.008   |
| Time to endoscopy, hour | 2.4 (0.4–45.0)  | 2.2 (0.4–5.9)    | 9.9 (6.0–45.0)    | <0.001  |
| Glasgow-Blatchford score| 11 (0–18)       | 11 (0–18)        | 10 (0–16)         | 0.334   |

Data are shown as median (range) or number (%).

BUN/Cr ratio, ratio of blood urea nitrogen to creatinine; DOAC, direct oral anticoagulant; NSAID, non-steroidal anti-inflammatory drug; SBP, systolic blood pressure

Regarding the presenting symptoms, 51.9% of the patients had hematemesis, and 40.7% had melena. When comparing the urgent and elective endoscopy group, median systolic blood pressure was significantly lower in the urgent group (p = 0.015). The GBS was 11 in the urgent group and 10 in the elective group, respectively (p = 0.334). The proportion of patients with GBS more than 7 was 75.1% (368/490) in the urgent group and 67.1% (55/82) in the elective group (p = 0.135).

Endoscopic findings and clinical outcomes

The median time to endoscopy was 2.4 hours (range, 0.4–45.0 hours). Endoscopic diagnoses included peptic ulcer (n = 310, 54.2%), gastroesophageal varix (n = 142, 24.8%), Mallory-Weiss syndrome (n = 49, 8.6%), and malignancy (n = 31, 5.4%) (Table 2). Endoscopic treatment was performed in 338 (59.1%) patients, which was successful in 334 patients. Two patients with duodenal ulcers required trans-arterial embolization after failed endoscopic treatment. One patient who had gastric gastrointestinal stromal tumor underwent surgery, and the remaining patient with duodenal ulcer had conservative management after confirmation of the absence of contrast extravasation on computed tomography scan with angiography. In one patient, duodenal varix was found at endoscopic examination and embolization was performed immediately as the first-line treatment.
Table 2
Endoscopic findings and clinical outcomes

|                          | Total (N = 572) | Urgent (n = 490) | Elective (n = 82) | P value |
|--------------------------|----------------|------------------|------------------|---------|
| Diagnosis                |                |                  |                  |         |
| Peptic ulcer             | 210 (54.2)     | 260 (53.1)       | 50 (61.0)        | 0.569   |
| Malignancy               | 31 (5.4)       | 27 (5.5)         | 4 (4.9)          |         |
| Mallory-Weiss syndrome   | 49 (8.6)       | 46 (9.4)         | 3 (3.7)          |         |
| Gastroesophageal varix   | 142 (24.8)     | 124 (25.3)       | 18 (22.0)        |         |
| Others*                  | 40 (7.0)       | 33 (6.7)         | 7 (8.5)          |         |
| Endoscopic treatment     | 338 (59.1)     | 297 (60.0)       | 41 (50.0)        | 0.089   |
| Thermocoagulation        | 170 (29.7)     | 147 (30.0)       | 23 (28.0)        |         |
| Hemoclip                 | 22 (3.8)       | 21 (4.3)         | 1 (1.2)          |         |
| Injection                | 31 (5.4)       | 29 (5.9)         | 2 (2.4)          |         |
| Band ligation            | 139 (24.3)     | 122 (24.9)       | 17 (20.7)        |         |
| Combination              | 42 (7.3)       | 37 (7.6)         | 5 (6.1)          |         |
| Embolization             | 3 (0.5)        | 3 (0.6)          | 0                | 1.000   |
| RBC transfusion, unit    | 2 (0–16)       | 2 (0–16)         | 2 (0–8)          | 0.346   |
| Rebleeding (n = 571)     | 34 (6.0)       | 29 (5.9)         | 5 (6.1)          | 1.000   |
| Mortality                | 31 (5.4)       | 26 (5.3)         | 5 (6.1)          | 0.791   |
| Hospital stay, days      | 6 (1–128)      | 6 (1–128)        | 6 (1–86)         | 0.401   |

*Others include marginal ulcer, acute gastric mucosal lesion, angioectasia, tuberculosis, esophageal ulcer, jejunal ulcer, gastrointestinal stromal tumor, and neuroendocrine tumor.

Mortality rate within 30 days was 5.4% in total (31/572), 5.3% (26/490) in the urgent endoscopy group and 6.1% (5/82) in the elective endoscopy group, respectively (p = 0.791) (Fig. 1). In-hospital death occurred in 23 patients; the cause of death was hypovolemic shock associated with uncontrolled bleeding in 4 patients, and hepatic failure in 11 patients. Rebleeding rate was assessed in 571 patients, excluding the patient who underwent embolization immediately after endoscopy. Rebleeding rate within 30 days was 6.0% (34/571) in total, 5.9% (29/489) in the urgent group, and 6.1% (5/82) in the elective group, respectively (p = 1.000). The median duration of hospital stay and amount of transfused RBC did not differ between two groups.
Among various clinical characteristics, age and amount of RBC transfusion were factors associated with mortality in univariate analysis (Table 3). Multivariate analysis showed that age (OR 1.038, 95% CI 1.008–1.069, $p = 0.013$) and RBC transfusion (OR 1.384, 95% CI, 1.178–1.627, $p < 0.001$) were associated with mortality.

| Table 3  | Factors associated with mortality |
|----------|----------------------------------|
|          | Univariate analysis | Multivariate analysis |
|          | OR      | 95% CI  | $P$ value | OR      | 95% CI  | $P$ value |
| Age      | 1.035   | 1.006–1.064 | 0.017     | 1.038   | 1.008–1.069 | 0.013     |
| Comorbidity | 3.659  | 0.860–15.569 | 0.079     |
| Glasgow-Blatchford score | 1.115  | 0.999–1.243 | 0.051     | 1.045   | 0.926–1.180 | 0.476     |
| RBC transfusion | 1.391  | 1.194–1.621 | $<0.001$ | 1.384   | 1.178–1.627 | $<0.001$ |
| Urgent endoscopy | 0.863  | 0.322–2.335 | 0.863     |

Discussion

In this study, we compared clinical outcomes of 572 patients suspected of acute UGIB according to the timing of emergency endoscopy. The mortality rate within 30 days and recurrent bleeding rate did not differ between the patients who underwent urgent endoscopy within 6 hours from presentation and those thereafter. Logistic regression analysis also showed that urgent endoscopy was not associated with mortality, while age and the amount of transfusion were factors associated with mortality.

Most guidelines recommend performing endoscopy within 24 hours in patients with acute UGIB $3^{–6}$. Endoscopy performed within 24 hours was associated with reduced length of hospital stay, and delayed endoscopy was associated with higher mortality in patients with UGIB $8^{,15}$. However, previous studies have shown conflicting results as to whether the earlier endoscopy within 6 to 12 hours from presentation can offer more benefit for patients with UGIB. A retrospective study of 934 high-risk patients with GBS of $\geq 12$ found that endoscopy performed within 13 hours resulted in lower mortality rate and shorter hospital stays than later endoscopy $9$. In addition, a cohort study showed that urgent endoscopy within 6 hours was an independent predictor of lower mortality rate compared with elective endoscopy (6–48 hours) in high-risk patients with GBS $>7^{10}$.

In contrast to these results, a retrospective study of 169 patients with acute non-variceal UGIB revealed no significant difference in mortality rate, rebleeding rate, and hospital stays between patients receiving endoscopy within 6 hours and within 24 hours $^{16}$. Similarly, another study showed that early endoscopy
within 12 hours was not associated with a lower mortality compared with later endoscopy within 24 hours. In a recent randomized controlled trial, a total of 516 high-risk patients (GBS of ≥ 12) with overt signs of acute UGIB, including variceal bleeding, were randomized to urgent (within 6 hours after gastroenterologic consultation) and early (within hours) endoscopy groups. Of note, some patients were not treated as assigned because of hemodynamic instability or changes in their medical conditions. There was no significant difference between the urgent and early groups in mortality rate (8.9% vs 6.6%, hazard ratio, 1.35; 95% CI, 0.72–2.54) and rebleeding rate (10.9% vs 7.8%, hazard ratio, 1.46; 95% CI, 0.83–2.58). In the present study, we included all patients who presented to emergency room with symptoms suggestive of UGIB regardless of the final diagnosis. The 30-day mortality rate and rebleeding rates did not differ between the patients who underwent endoscopy within 6 hours and those who underwent endoscopy after 6 hours. These results support recent guidelines that recommends performing endoscopy within 24 hours following hemodynamic resuscitation in patients with UGIB and does not recommend earlier (within 12 hours) endoscopy.

Endoscopy performed early in the clinical course was considered useful to triage patients based on the endoscopic findings. Patients with low risk of recurrent bleeding could be discharged earlier. In addition, early intervention within 24 hours was associated with shorter length of hospital stay. In contrast, some studies suggested that earlier endoscopy may yield more high-risk endoscopic stigmata that would have been resolved with proton pump inhibitor therapy. A previous study showed that more retained blood and more actively bleeding lesions were found in patients who underwent endoscopic examination within 8 hours from presentation compared with those who underwent endoscopy between 8 to 24 hours. Recent randomized trial also showed that patients with active bleeding or visible vessel and those who required endoscopic treatment were more frequently found in the urgent endoscopy (within 6 hours after gastroenterologic consultation) group than in the early endoscopy (within 24 hours) group. In the present study, we found that the proportion of patients who underwent endoscopic treatment was higher in the urgent group than in the elective group, and the need for endoscopic treatment was not associated with reduced recurrent bleeding. These results suggest that initial hemodynamic resuscitation and proton pump inhibitor therapy are more beneficial than earlier endoscopy within 6 hours when it comes to improving clinical outcomes.

Several factors have been reported to be associated with mortality in patients with UGIB, including comorbidities, vital signs, and failed endoscopic treatment. In the present study, the clinical factors associated mortality were age and RBC transfusion. Previous observational study investigated 186 patients in Korea also showed that age (≥ 65 years) was an independent predictive factor for mortality. Worse outcomes in the elderly might be attributable to tendency to having multiple comorbidities and susceptibility to physiological changes of elderly patients. There were also discrepancies regarding the impact of RBC transfusion on mortality in previous studies. It may be resulted from differences in demographics of patients and study design, and further studies containing various demographic characteristics are needed to identify clinical factors affecting outcomes of patients with acute UGIB.
There are several limitations in this study. First, this is a retrospective study. Although it is desirable to design randomized control trial, performing such kind of study would be difficult and should consider ethical issue because delay in endoscopic procedure may lead to fatal outcomes. Future prospective study would be beneficial to confirm the limited role of urgent endoscopy. Second, because this is a single-center study, the results may not represent the overall national demographics. Indeed, most endoscopic examination was performed within 6 hours in our center. Since the resources required to emergency procedure are limited, the results of this study cannot be generalized. Another possible limitation of this study is that our study population consists of heterogeneous patients, including gastroesophageal variceal bleeding. However, in a clinical practice, it is often challenging to discriminate patients with variceal bleeding from non-variceal bleeding at the time of presentation, even after thorough history taking. Since the decision whether to perform endoscopy immediately or not is made based on information obtained at the presentation, it was assumed to be reasonable to include all patients suspected as having UGIB to determine the role of urgent endoscopy in real-world.

In conclusion, urgent endoscopy within 6 hours was not significantly associated with lower mortality and rebleeding rate. We also found that age and RBC transfusion were the factors related to mortality. Based on these findings, we suggest performing elective endoscopy after hemodynamic stabilization including restricted transfusion in patients with suspected acute UGIB.

Declarations

Competing interests

All authors declare no potential conflicts of interest regarding this manuscript.

Acknowledgments

None

Funding

This research was supported by Medical Research Promotion Program through the Gangneung Asan Hospital funded by the Asan Foundation (2020IB003).

Author contributions

Conceptualization: J.K., E.J.G., H.I.S.

Data collection: J.K., E.J.G., M.S., J.K.P., S.J.L.

Data analysis and interpretation: J.K., E.J.G., H.I.S.

Writing – original draft: J.K., E.J.G.
References

1  Hearnshaw, S. A. et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. *Gut* **60**, 1327-1335, doi:10.1136/gut.2010.228437 (2011).

2  Laine, L. & McQuaid, K. R. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. *Clin Gastroenterol Hepatol* **7**, 33-47; quiz 31-32, doi:10.1016/j.cgh.2008.08.016 (2009).

3  Sung, J. J. et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. *Gut* **67**, 1757-1768, doi:10.1136/gutjnl-2018-316276 (2018).

4  Barkun, A. N. et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. *Ann Intern Med* **171**, 805-822, doi:10.7326/M19-1795 (2019).

5  Gralnek, I. M. et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. *Endoscopy* **53**, 300-332, doi:10.1055/a-1369-5274 (2021).

6  Kim, J. S. et al. Guidelines for Nonvariceal Upper Gastrointestinal Bleeding. *Gut Liver* **14**, 560-570, doi:10.5009/gnl20154 (2020).

7  Lau, J. Y. W. et al. Timing of Endoscopy for Acute Upper Gastrointestinal Bleeding. *N Engl J Med* **382**, 1299-1308, doi:10.1056/NEJMoa1912484 (2020).

8  Tai, C. M. et al. High-risk ED patients with nonvariceal upper gastrointestinal hemorrhage undergoing emergency or urgent endoscopy: a retrospective analysis. *Am J Emerg Med* **25**, 273-278, doi:10.1016/j.ajem.2006.07.014 (2007).

9  Lim, L. G. et al. Urgent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleeding. *Endoscopy* **43**, 300-306, doi:10.1055/s-0030-1256110 (2011).

10  Cho, S. H. et al. Outcomes and Role of Urgent Endoscopy in High-Risk Patients With Acute Nonvariceal Gastrointestinal Bleeding. *Clin Gastroenterol Hepatol* **16**, 370-377, doi:10.1016/j.cgh.2017.06.029 (2018).

11  Laursen, S. B. et al. Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. *Gastrointest Endosc* **85**, 936-944 e933, doi:10.1016/j.gie.2016.08.049 (2017).
Kumar, N. L., Cohen, A. J., Nayor, J., Claggett, B. L. & Saltzman, J. R. Timing of upper endoscopy influences outcomes in patients with acute nonvariceal upper GI bleeding. *Gastrointest Endosc* **85**, 945-952 e941, doi:10.1016/j.gie.2016.09.029 (2017).

Srygley, F. D., Gerardo, C. J., Tran, T. & Fisher, D. A. Does this patient have a severe upper gastrointestinal bleed? *Jama* **307**, 1072-1079, doi:10.1001/jama.2012.253 (2012).

Blatchford, O., Murray, W. R. & Blatchford, M. A risk score to predict need for treatment for upper gastrointestinal haemorrhage. *The Lancet* **356**, 1318-1321, doi:10.1016/s0140-6736(00)02816-6 (2000).

Jeong, N., Kim, K. S., Jung, Y. S., Kim, T. & Shin, S. M. Delayed endoscopy is associated with increased mortality in upper gastrointestinal hemorrhage. *Am J Emerg Med* **37**, 277-280, doi:10.1016/j.ajem.2018.05.049 (2019).

Targownik, L. E., Murthy, S., Keyvani, L. & Leeson, S. The role of rapid endoscopy for high-risk patients with acute nonvariceal upper gastrointestinal bleeding. *Canadian journal of gastroenterology = Journal canadien de gastroenterologie* **21**, 425-429, doi:10.1155/2007/636032 (2007).

Jairath, V. *et al.* Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. *Endoscopy* **44**, 723-730, doi:10.1055/s-0032-1309736 (2012).

Cooper, G. S. *et al.* Early endoscopy in upper gastrointestinal hemorrhage: associations with recurrent bleeding, surgery, and length of hospital stay. *Gastrointest Endosc* **49**, 145-152, doi:10.1016/s0016-5107(99)70478-5 (1999).

Lau, J. Y. *et al.* Omeprazole before endoscopy in patients with gastrointestinal bleeding. *N Engl J Med* **356**, 1631-1640, doi:10.1056/NEJMoa065703 (2007).

Lee, Y. J. *et al.* Predictive factors of mortality within 30 days in patients with nonvariceal upper gastrointestinal bleeding. *Korean J Intern Med* **31**, 54-64, doi:10.3904/kjim.2016.31.1.54 (2016).

Jimenez-Rosales, R. *et al.* Inhospital and delayed mortality after upper gastrointestinal bleeding: an analysis of risk factors in a prospective series. *Scand J Gastroenterol* **53**, 714-720, doi:10.1080/00365521.2018.1454509 (2018).

Fukuda, S. *et al.* Risks for Rebleeding and In-Hospital Mortality after Gastrointestinal Bleeding in a Tertiary Referral Center in Japan. *Digestion* **101**, 31-37, doi:10.1159/000504088 (2020).

Bishay, K. *et al.* Clinical Factors Associated with Mortality in Cirrhotic Patients Presenting with Upper Gastrointestinal Bleeding. *J Can Assoc Gastroenterol* **3**, 127-134, doi:10.1093/jcag/gwy075 (2020).
Figures

Figure 1

Mortality and recurrent bleeding rates within 30 days in study population. (A) Mortality rate did not differ between the urgent (≤6 hours from presentation) and elective (>6 hours from presentation) endoscopy groups, (B) recurrent bleeding rate did not differ between the two groups.

\[ p = 0.791 \]

\[ p = 1.000 \]